Compare Raytheon Technologies Corp (RTX) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raytheon Technologies Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Raytheon Technologies Corp trades at $223.95 (market cap $302.06B), while Vertex Pharmaceuticals Incorporated trades at $529.7 (market cap $132.79B). The key difference: Raytheon Technologies Corp is far larger — about 2.3× Vertex Pharmaceuticals Incorporated's market cap, and Raytheon Technologies Corp pays a 1.3% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| RTX | VRTX | |
|---|---|---|
Market Cap | $302.06B | $132.79B |
Sector | Industrials | Health |
52-Week High | $224.12 | $529.59 |
52-Week Low | $151.75 | $374.46 |
Enterprise Value | $332.61B | $126.92B |
Dividend Yield | 1.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RTX trades at $223.03, down 0.1% on the day, with a bullish technical outlook supported by moving averages and a recent $515 million Navy radar contract. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue grew to $88.6 billion in 2025, and net income margin improved to 8.28%. The stock is near its consensus price target of $233.14, with no analyst sell ratings.
The outlook for RTX is positive, driven by defense contract wins and expanding profit margins, but risks include high valuation multiples and geopolitical uncertainties. Earnings growth and execution on backlog are key catalysts for further upside, though the stock's elevated P/E ratio of 39.27 warrants caution amid potential market volatility.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
